Cargando…

Immunotherapy trials in Parkinson’s disease: challenges

Detalles Bibliográficos
Autores principales:	Xiao, Bin, Tan, Eng-King
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987107/ https://www.ncbi.nlm.nih.gov/pubmed/36879300 http://dx.doi.org/10.1186/s12967-023-04012-x

Ejemplares similares

Cell replacement for Parkinson’s disease: advances and challenges
por: Xiao, Bin, et al.
Publicado: (2023)

Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges
por: Xiao, Bin, et al.
Publicado: (2016)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Mitophagy and reactive oxygen species interplay in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Combination therapy using GDNF and cell transplant in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Familial Parkinson's Disease/Parkinsonism
por: Tomiyama, Hiroyuki, et al.
Publicado: (2015)

Neuroimaging in Parkinsonism: Insights and Challenges
por: Sharma, Vibhash D.
Publicado: (2023)

Potential impact and challenges associated with Parkinson’s disease patient care amidst the COVID-19 global pandemic
por: Elbeddini, Ali, et al.
Publicado: (2020)

Sleep Problems in Parkinson's Disease
por: Hirata, Koichi, et al.
Publicado: (2015)

Is immunotherapy an effective treatment for Alzheimer's disease?
por: Licastro, Federico, et al.
Publicado: (2004)

Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges
por: Xing, Shuqin, et al.
Publicado: (2022)

Historical Perspective: Models of Parkinson’s Disease
por: Chia, Shyh Jenn, et al.
Publicado: (2020)

Evidence of Inflammatory System Involvement in Parkinson's Disease
por: Chao, Yinxia, et al.
Publicado: (2014)

Role of dopamine in the pathophysiology of Parkinson’s disease
por: Zhou, Zhi Dong, et al.
Publicado: (2023)

Repurposing infectious disease vaccines for intratumoral immunotherapy
por: Melero, Ignacio, et al.
Publicado: (2020)

Cancer immunotherapy trials: leading a paradigm shift in drug development
por: Emens, Leisha A., et al.
Publicado: (2016)

Recruitment of patients with de novo Parkinson disease: successful strategies in a randomized exercise clinical trial
por: Hall, Deborah A., et al.
Publicado: (2018)

When could human challenge trials be deployed to combat emerging infectious diseases? Lessons from the case of a Zika virus human challenge trial
por: Palacios, Ricardo, et al.
Publicado: (2019)

Self-Image in Women with Parkinson’s Disease
por: Mathur, Soania, et al.
Publicado: (2023)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Understanding of skeletal deformities in Parkinson's disease
por: Baik, Jong Sam
Publicado: (2016)

Impact of COVID‐19 pandemic on patients with Parkinson's disease: A meta‐analysis of 13,878 patients
por: Mai, Aaron Shengting, et al.
Publicado: (2022)

Linking restless legs syndrome with Parkinson's disease: clinical, imaging and genetic evidence
por: Peeraully, Tasneem, et al.
Publicado: (2012)

Immunotherapy for Parkinson’s disease
por: Schwab, Aaron D., et al.
Publicado: (2020)

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
por: Masucci, Giuseppe V, et al.
Publicado: (2012)

Antigen-specific immunotherapy for MOG antibody-associated diseases
por: Nessler, Stefan
Publicado: (2019)

Leucine-Rich Repeat Kinase 2-Linked Parkinson’s Disease: Clinical and Molecular Findings
por: Kumari, Udhaya, et al.
Publicado: (2010)

Hopamine as Personalized Medicine for Persons with Parkinson’s Disease
por: Noordegraaf, Marina A., et al.
Publicado: (2023)

Parkinson's disease in the elderly and the comprehensive geriatric assessment
por: Lauretani, Fulvio
Publicado: (2013)

Testing the Protein Propagation Hypothesis of Parkinson Disease
por: Dagher, Alain, et al.
Publicado: (2018)

Future of Monoclonal Antibody Therapy in Parkinson’s Disease
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Parkinson's Disease Caregiver Strain in Singapore
por: Tan, Siok-Bee, et al.
Publicado: (2020)

Parkinson’s disease GWAS-linked Park16 carriers show greater motor progression
por: Deng, Xiao, et al.
Publicado: (2019)

New Insights into Immune-Mediated Mechanisms in Parkinson’s Disease
por: Tan, Jolene Su Yi, et al.
Publicado: (2020)

Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxis
por: Tan, Darrell H. S., et al.
Publicado: (2020)

Chagas Disease — An Underestimated Global Public Health Challenge
por: Liu, Qin, et al.
Publicado: (2020)

The pons and human affective processing — Implications for Parkinson's disease
por: Huot, Philippe
Publicado: (2015)

Novel gene (TMEM230) linked to Parkinson’s disease
por: Olszewska, Diana A., et al.
Publicado: (2016)

The understanding of Parkinson's disease through genetics and new therapies
por: Uwishema, Olivier, et al.
Publicado: (2022)

Targets for astrocyte-based treatments of Parkinson’s disease (PD)
por: Parmar, Malin
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rhalojpcelsie69ubejpk2rft7